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Histomorphological features of colorectal cancers (CRC) represent valuable prognostic
indicators for clinical decision making.The invasive margin is a central feature for prognos-
tication shaped by the complex processes governing tumor–host interaction. Assessment
of the tumor border can be performed on standard paraffin sections and shows promise
for integration into the diagnostic routine of gastrointestinal pathology. In aggressive CRC,
an extensive dissection of host tissue is seen with loss of a clear tumor–host interface.
This pattern, termed “infiltrative tumor border configuration” has been consistently associ-
ated with poor survival outcome and early disease recurrence of CRC-patients. In addition,
infiltrative tumor growth is frequently associated with presence of adverse clinicopatho-
logical features and molecular alterations related to aggressive tumor behavior including
BRAFV600 mutation. In contrast, a well-demarcated “pushing” tumor border is seen fre-
quently in CRC-cases with low risk for nodal and distant metastasis. A pushing border is a
feature frequently associated with mismatch-repair deficiency and can be used to identify
patients for molecular testing. Consequently, assessment of the tumor border configu-
ration as an additional prognostic factor is recommended by the AJCC/UICC to aid the
TNM-classification. To promote the assessment of the tumor border configuration in stan-
dard practice, consensus criteria on the defining features and method of assessment need
to be developed further and tested for inter-observer reproducibility. The development of
a standardized quantitative scoring system may lay the basis for verification of the prog-
nostic associations of the tumor growth pattern in multivariate analyses and clinical trials.
This article provides a comprehensive review of the diagnostic features, clinicopathological
associations, and molecular alterations associated with the tumor border configuration in
early stage and advanced CRC.
Keywords: tumor border configuration, invasive margin, tumor growth pattern, infiltrative border, pushing border,
colorectal cancer, prognostic factor, tumor–host interaction
INTRODUCTION
Prognostication of colorectal cancer (CRC) is based on histopatho-
logical staging of the resection specimen according to the
AJCC/UICC TNM-classification and guides treatment decisions.
The TNM-classification requires reporting of local tumor extent,
status of regional nodes, lymphatic and blood vessel invasion,
and residual tumor as essential prognostic factors (1). Additional
histomorphological indicators are tumor grade, tumor budding,
and tumor border configuration (1). Even though the TNM-
classification is the gold standard in clinical practice, some patients
with lower TNM-stages show a worse prognosis compared to
patients with a higher tumor stage. This holds true for selected
stage I CRC-patients, some of which paradoxically relapse with
nodal metastasis after removal of an early invasive lesion (2). Iden-
tification of these patients for segmental resection is of paramount
importance for a risk-adapted treatment approach. Further, locally
advanced nodal-negative stage II CRC can behave aggressively in
the presence of additional histomorphological risk factors (3, 4).
In particular, nodal-negative stage II patients with serosal per-
foration, lymphovascular invasion, perineural infiltration, or an
invasive tumor border configuration may have a comparable out-
come to stage III patients with nodal positive disease, but do not
yet receive neoadjuvant treatment as a standard of care (5–7).
Several recent clinical studies have explored the use of
chemotherapeutic treatment in stage II patients with mixed results.
A meta-analysis of the available literature by the American Soci-
ety of Clinical Oncology (ASCO) failed to identify a significant
benefit in overall survival of stage II patients receiving adjuvant
therapy (8). Consequently, the ASCO does not recommend rou-
tine use of chemotherapy in stage II CRC-patients. However, use of
adjuvant therapy is considered justified in well-informed patients
with additional risk factors such as inadequately sampled nodes,
T4 lesions, perforation, or poorly differentiated histology (8). The
recent QUASAR trial provides further evidence of an incremental
benefit of adjuvant therapy in stage II patients with a signifi-
cant decrease in disease recurrence and a 3–6% improvement in
survival in patients receiving adjuvant chemotherapy (4). From
the pathologist’s perspective, the recognition, standardization, and
reporting of histomorphological prognostic features are an impor-
tant basis for identification of patient subgroups with a higher risk
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FIGURE 1 | (A) Low power image (5×) of a H&E slide and pan-cytokeratin
(brown)/CD8 (red) double stain illustrating a transmurally invasive primary
CRC with an infiltrative tumor border configuration. Delineation of tumor and
host tissue is difficult in the H&E stain. Residual host tissue is present
between infiltrating cords and sharp wedges of long-stretched tumor glands.
(B) High power detail (20×) of (A). Note the diffuse dissection of irregularly
shaped tumor glands through the mesenteric adipose tissue. CD8+
lymphocytes at the tumor invasive front are infrequent (arrows). Tumor buds
invading the stroma ahead of the invasive front can be identified as a
superimposed feature (arrow heads).
of recurrence (9). Clinically, these patients may then benefit from
individualized therapeutic approaches and enrollment in clinical
trials.
This article provides a comprehensive review on the pathol-
ogy, biology, and prognostic value of tumor border configuration
in CRC. An irregular, “infiltrative” advancing edge is a hallmark
of highly aggressive tumors and has been classified as an inde-
pendent adverse prognostic indicator and may predict propensity
for systemic spread of disease in colon and rectal cancer (10–
16). In contrast, tumors demonstrating a smooth demarcation
with a rounded infiltrative border are classified as having an
“expansile” or “pushing” border configuration. As will be dis-
cussed in detail, this feature is predictive of limited tumor aggres-
siveness and is often seen in mismatch-repair (MMR) deficient
CRCs (17–19). The addition of tumor border configuration to
TNM-staging may help to stratify CRC-patients of a given stage
into diagnostic subgroups (7). Importantly, this adverse prog-
nostic feature can be easily detected on standard H&E slides
by the histopathologist and is recommended for routine report-
ing of transmurally invasive CRC as a category IIB prognostic
factor (20).
SURGICAL PATHOLOGY
The histomorphological variance of the tumor border configura-
tion of CRC was first described by Jass in 1986 as an important
histomorphological prognostic indicator in rectal cancer patients
(21). Methodologically, tumor border configuration is a feature
diagnosed at low magnification and must be clearly differentiated
from diagnostic features seen at high power such as tumor budding
(10). According to Jass, an infiltrative border configuration should
already be suspected when examination of the histopathologic
slide with the naked eye does not allow a clear definition of the
invasive margin and it seems impossible to resolve host tissue
from malignant glands (Figure 1A) (21–23). At low magnifica-
tion, tumors with an infiltrative growth pattern show dissection
of tumor tissue through the anatomic structures of the bowel wall
with little or absent desmoplastic stromal response (21–23). The
dissecting tumor glands often form irregular clusters or cords of
cells, long-stretched glandular structures, or sharp wedges leaving
residual host tissue in between, a pattern termed“streaming dissec-
tion” (Figure 1B) (10, 11, 23, 24). Presence of perineural invasion
on the histologic slide is a further indicator of diffuse infiltration
(23). In contrast, a pushing tumor border configuration should
be suspected when naked eye examination of the histologic slide
allows a clear delineation of the tumor invasive front and host
tissue (Figure 2A). Under low magnification, a round “circum-
scribed”configuration of the infiltrative margin is characteristic of
the “pushing” pattern of infiltration (23). Widely dissecting tumor
glands in the muscularis propria or mesenteric adipose tissue are
absent (Figure 2B).
Infiltrative growth is often observed as a heterogeneously dis-
tributed feature in CRC and a majority of cases demonstrate a
predominant or at least focally infiltrative tumor border configu-
ration, leading to variability in interpretation. According to Jass,
the tumor border configuration is classified as either infiltrat-
ing or pushing in a two-tier system (22). This recommendation
has been adapted in the CAP reporting standards for CRC (11).
However, other authors have advocated the use of a trichotomous
classification and to restrict the “infiltrating” pattern to cases with
an unequivocal infiltrating growth involving the complete tumor
border (25). All of the criteria used to differentiate the pushing
from the infiltrative tumor border configuration share a subjective,
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FIGURE 2 | (A) Low power image (5×) of a H&E slide and pan-cytokeratin
(brown)/CD8 (red) double stain demonstrating a primary CRC with a pushing
tumor border configuration of growth. The tumor border is round and
well-recognizable at low magnification. Tumor and host tissue can be easily
differentiated. Host tissue is displaced by expansile tumor growth. (B) High
power detail (20×) of (A). CD8+ lymphocytes are commonly observed
(arrows). Tumor budding can be recognized as a superimposed feature but is
generally infrequent (arrow heads).
qualitative nature, and a hierarchy of features have not been des-
ignated. This may lead to a very variable classification of cases
showing a mixed morphology with either the infiltrating or push-
ing subset. Further, there is currently no clear consensus on the
minimum extension of the infiltrative component necessary to
designate a case as having an infiltrative tumor border config-
uration. While some authors require a predominant infiltrative
growth pattern for this classification and describe as few as 17%
of CRCs as infiltrative, others have included any case with at least
focal infiltrative growth pattern assigning up to 70% of CRC-cases
to the infiltrative group (7, 13). Consequently, a suboptimal inter-
observer reproducibility has been described for the assessment of
tumor border configuration according to the Jass criteria, but can
be improved by educating the observers to the defining features
(23). Thus, a standardization of the pathologic quantification of
the invasive growth pattern is urgently needed to advance its use
in daily diagnostic practice.
Tumor budding, defined as the presence of single cells or small
clusters of up to five cells ahead of the invasive front, is frequently
observed as a superimposed pattern in cases with an infiltra-
tive tumor border configuration (Figure 3) (26). However, tumor
budding is a separate, independent feature observed at high mag-
nification and must not be used to differentiate infiltrative from
pushing tumor growth (9). The presence of tumor budding is an
increasingly important histomorphological prognostic factor in
CRC (11, 24, 27). Biologically, tumor budding is likely the visi-
ble correlate of the process of epithelial mesenchymal transition,
during which cancer cells, epithelial by nature, acquire mesenchy-
mal characteristics with capability for migration, stromal lysis, and
vascular invasion (28). In early stage CRC, the presence of tumor
budding can be indicative of clinical undetectable micrometastases
FIGURE 3 | High power image (40×) of a pan-cytokeratin (brown)/CD8
(red) double stain illustrating dense tumor budding at the tumor
invasive front. Tumor buds (arrow heads) are defined as single cells or
small clusters of up to five cells ahead of the tumor invasive front.
High-grade tumor budding is a feature of aggressive biological behavior in
colorectal cancer. Even though tumor budding is more frequently observed
in cases with an infiltrative tumor border configuration, this is an
independent feature observed at high power and must not be used to
define the quality of the tumor border.
present already at the time of resection of the primary tumor
(29). In locally advanced CRC, the presence of tumor budding
is an important prognostic indicator for a reduced 5-year sur-
vival outcome with elevated risk for disease relapse (27, 30–34).
Consequently, tumor budding has been designated a category IIB
prognostic factor by the CAP (20).
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PROGNOSTIC IMPACT
EARLY STAGE CRC
Early stage CRC is treated by endoscopic or surgical resection as
standard of care. Consequently, the prediction of local recurrence
and nodal metastasis by assessment of histopathological features
of early invasive CRC is of central importance for patient treat-
ment and follow-up. Several retrospective correlative studies have
addressed the prognostic value of the tumor border configura-
tion in early stage CRC (Table 1) and have reported conflicting
evidence: in curatively resected submucosally invasive CRC, both
Egashira (n= 140) and Wang (n= 159) failed to identify an asso-
ciation of tumor growth pattern with nodal metastasis (32, 35). In
contrast, Keum and colleagues characterize an infiltrating pattern
of growth as opposed to a smooth pushing border as a significant
independent predictor for disease recurrence in an analysis of 434
patients who underwent curative resection for stage I CRC (36).
Further, in an analysis of 111 submucosally invasive pT1 CRC-
cases,Akishima-Fukasawa et al. describe the invasive tumor border
configuration to be a highly significant predictor of regional lymph
node metastasis in univariate but not in multivariate analysis (37).
This data is expanded for stage I patients with muscularis propria
invasion by Kajiwara and associates who demonstrate an increased
frequency of nodal involvement in patients with an infiltrative
tumor border configuration in univariate but not in multivari-
ate analysis (38). Taken together, there is a lack of conclusive data
on the prognostic value of invasive border configuration in early
stage CRC. This may be due to absence of standardized criteria for
pathologic assessment. Further, the assessment of the predominant
growth pattern in early invasive CRC may be restricted because of
limited invasive tumor tissue. As a result, the recommendation
for the assessment of tumor border configuration by the AJCC is
currently limited to transmurally invasive CRCs (20).
ADVANCED CRC
In transmurally invasive CRC, an infiltrative tumor border con-
figuration has been established as an adverse prognostic factor in
several well-designed retrospective cohort studies including CRC-
patients of all stages (Table 2). In detail, assessment of the tumor
border configuration was found to provide stage-independent
prognostic information on the relative risk for disease recurrence
and cancer-related death after resection of the primary tumor
aiding the TNM- and Dukes-classification (7, 12, 13, 15, 25, 26,
39, 40). The prognostic value of tumor border configuration in
locally advanced CRC is supported by several multivariate analy-
ses on independent patient cohorts leading to a recommendation
for routine reporting by the CAP (20). Recent data also indicate
that the prognostic value of the tumor growth pattern in stage
I–III CRC is independent of central molecular features including
KRAS, BRAF, and PIK3CA mutations as well as MSI-status and
CIMP methylation (25). Assessment of the tumor border configu-
ration should therefore be included in daily diagnostic practice to
aid selection of high risk CRC-patients that could derive the most
benefit from adjuvant multi-agent therapy.
Several studies have also analyzed the prognostic value of tumor
border configuration in locally advanced CRC stratified by stage.
The results suggest that additional prognostic information is car-
ried by this feature in patients with stage II, nodal-negative CRC.
In a cohort of 238 well-characterized stage IIA CRC-patients,
Cianchi et al. provide comprehensive evidence of a significantly
elevated risk of cancer-specific death in patients with an infil-
trative vs. pushing tumor border configuration: 5-year survival
rates are specified as 81.8% with an infiltrating tumor border as
opposed to 92.9% in cases demonstrating an expansile growth
pattern (p< 0.01) (43). Ueno and colleagues confirm these find-
ings in a study of 994 CRC-cases including 434 stage II and 560
stage III patients reporting a 5-year survival rate of 81.8% for the
infiltrating group, compared to 92.9% when an expansile border
configuration was recorded (p= 0.015) (39). This preliminary evi-
dence suggests that the assessment of tumor border configuration
may be a promising additional risk-indicator in stage II disease.
Assessment of this feature could aid the selection of high risk stage
II patients for adjuvant multi-agent therapy and should be inves-
tigated further in large randomized multi-center trials to build a
reliable evidence base.
The prognostic value of the tumor border configuration in
advanced CRC is further supported by correlation with vascular
invasion, which is another established feature of aggressive disease.
In an analysis of 994 stage II–III patients, Ueno and colleagues
describe a strong relation of an infiltrative growth pattern in the
muscularis propria to the presence of hemangioinvasion at the
invasive front of CRC (39). This data is expanded in a study of 427
stage I–IV CRC-patients by Zlobec and associates who describe a
significantly increased frequency of vascular invasion in tumors
with an infiltrative growth pattern (40). Further, tumor border
configuration was identified as a decisive classifier for the iden-
tification of tumors with vascular invasion when combined with
expression of Raf-kinase inhibitor protein (RKIP), urokinase plas-
minogen activator receptor (µPAR), and the proliferative index.
As RKIP and µPAR are important biomarkers of tumor motility
and invasive capacity, this provides further evidence for an elevated
risk of distant metastasis predicted by the tumor growth pattern.
Interestingly, an infiltrative tumor border configuration is also
strongly predictive of high-grade tumor budding, indicating that
the biological processes leading to the formation of tumor buds
and an invasive tumor border configuration may be inter-related
(39, 44). Patients presenting with both high-grade tumor budding
and an infiltrative tumor border configuration have an increased
risk of cancer-related death than patients presenting with either
alone (39).
Taken together, a solid evidence base for the prognostic value of
tumor border configuration exists in advanced CRC and standard
reporting of this feature is recommended for diagnostic practice
(20). Nevertheless, in order to definitively evaluate the prognostic
importance of tumor border configuration in CRC, statistically
robust studies with multivariate analysis and standardized crite-
ria for pathologic assessment will be required, particularly for the
stage II subset.
BIOLOGICAL ASPECTS
The invasive front of CRC embodies the tumor–host interface.
Thus, it can be assumed that the histomorphological appearance
of this region is the result of the interaction between host and
tumor-related factors. Specifically, the dynamics of tumor cell pro-
liferation and expansion is likely governed by specific molecular
Frontiers in Oncology | Gastrointestinal Cancers February 2014 | Volume 4 | Article 29 | 4
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alterations in cancer cells (46): the individual appearance of the
tumor invasive margin will reflect the capacity of tumors to pro-
liferate, migrate, and invade the surrounding stroma. An invasive
tumor margin may therefore be the morphological snapshot of
directed migration of tumor cells into host tissue after division
(47). As tumor cell crowding inhibits growth and proliferation, it
can be expected that directed growth also correlates with higher
rates of tumor expansion (48). In contrast, a pushing margin may
represent the random arrangement of tumor cells after division
leading to the formation of static round tumor cell clusters with
less propensity or capability for invasion of host tissue. Remark-
ably, primary CRC with a pushing margin also preferentially cause
capsulated liver metastasis while cases with infiltrative tumor
growth tend to form poorly demarcated lesions indicating that the
configuration of the tumor margin could be a conserved tumor
feature independent of the surrounding type or quality of host
tissue (49). Biologically, the formation of an infiltrative margin
may therefore be tantamount to the tendency for “directed tumor
growth” while a pushing margin could be the visual correlate of
“non-directed growth” in CRC.
Interestingly, the configuration of the invasive margin corre-
lates with some of the well-characterized molecular alterations
in CRC. Specifically, a well-demarcated, expansile tumor bor-
der is a feature frequently seen in MMR-deficient CRC-cases,
particularly in the setting of the hereditary non-polyposis col-
orectal cancer syndrome (HNPCC) (17–19). As only about 15%
of CRC-cases follow the microsatellite-instable pathway, mor-
phological features are a valuable tool to specifically select cases
for molecular testing (10, 18, 50). If a well-defined pushing
margin in addition to mucinous differentiation, solid growth
pattern, presence of intraepithelial lymphocytes, and Crohn’s-
like lymphocytic reaction is observed in a case with right-
sided location, the threshold for testing of microsatellite insta-
bility should be particularity low as these morphological fea-
tures reach a sensitivity of 78% and specificity of up 93% for
MMR-deficiency (18). In contrast, an infiltrating tumor growth
pattern is significantly more frequent in tumors with activat-
ing BRAF-mutations, while no impact of KRAS-mutations was
observed (25). While MMR-deficient CRC generally has a favor-
able outcome, BRAF is an independent predictor of an aggres-
sive clinical course (51–53). Interestingly, early functional data
indicates that constitutive activation of BRAF may increase the
migratory and invasive capacity of human colon cancer cells
(54). This could contribute to the significantly more frequent
invasive growth pattern observed in CRC-cases with activating
BRAF-mutations.
Host-related factors may also influence the appearance of the
tumor border in CRC. In a well-designed retrospective study
of 527 patients, Halvorsen et al. describe a marked absence of
peritumoral inflammation in patients with an infiltrative tumor
border configuration (12). In contrast, CRC-cases with a pushing
border have a well-characterized association with dense peritu-
moral inflammatory infiltrates (17–19). Interestingly, it is now
well-known that the quantity and quality of peritumoral inflam-
matory infiltrates is a significant independent predictor of survival
outcome and related to the efficiency of the anti-tumoral host
response, which may be a possible confounding factor of the prog-
nostic benefit of a pushing tumor border configuration (55–57).
Additionally, both features are characteristic of MMR-deficiency,
which may be a further hidden variable in early reports (17–
19). Both points have been addressed in recent studies. In an
analysis of MMR-proficient 269 patients, Zlobec and colleagues
demonstrate that an infiltrative tumor border configuration main-
tains association with local recurrence of CRC independently of
the quantity of CD8+ tumor-infiltrating lymphocytes (TIL) and
nodal status (26). In detail, node-negative, TIL-negative patients
with an infiltrative border configuration had a probability of 0.55
for recurrence whereas patients with a pushing border had a sig-
nificantly reduced probability of disease relapse of 0.26 (26). In
a study of 1139 well-characterized CRC-patients, Morikawa and
associates recently confirmed the absence of a modifying effect of
peritumoral lymphocytic infiltration on the prognostic value of
the tumor growth pattern (25).
Taken together, the tumor border is shaped both by tumor- and
host-related factors. A strong correlation with specific molecular
alterations has been described, providing further evidence that
specific molecular alterations may dictate the growth dynamics of
CRC. Importantly, specific BRAF-mutations and MMR-deficiency
are also predictive of response to targeted therapy with 5-FU and
Cetuximab-based therapy (58–60). Apart from the well-described
prognostic associations the tumor growth pattern could there-
fore also represent a surrogate morphological indicator for specific
molecular mutations with predictive value.
CONCLUSION
Evaluation of the tumor border configuration by the histopathol-
ogist identifies distinct subsets of primary CRC (Table 3) and
represents an important histomorphological prognostic indica-
tor. It can be assessed on standard H&E slides and is consistently
related to survival outcome of patients with transmurally invasive
CRC in statistically robust studies and multivariate analysis. How-
ever, the configuration of the tumor border is rarely reported in
daily diagnostic practice as its significance for prognostication in
CRC is not commonly recognized. Further, the subjective nature
and lack of standardization of the assessment method may limit
frequent reporting of this important feature in clinical practice.
The assessment of the tumor border configuration according to
the Jass criteria may profit from the development of a standardized
quantitative system and needs to be tested further for reproducibil-
ity. Methodologically, this may improve the current substantial
variation in assessment criteria between different authors and
may lay the basis for inclusion of tumor border configuration
as a feature for risk assessment in prospective randomized clinical
trials.
In early invasive disease, recent studies identify promising
associations with clinical outcome. However, evaluation in large,
randomized multi-center studies will be needed to conclusively
address possible associations of tumor growth pattern with out-
come in stage I CRC. For stage II CRC, the evidence base is
more consistent making the tumor growth pattern a promising
marker to identify high risk patients with locally advanced nodal-
negative disease for individualized therapy approaches. However,
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Table 3 | Contrasting features of primary colorectal cancers depending on the tumor border configuration.
Characteristics Infiltrative Pushing
Examination of the histopathologic
slide with the naked eye
No clear definition of the invasive margin is possible (23)
Difficulty in resolving host tissue from malignant glands (23)
Clearly recognizable invasive margin
Easy delineation of host and malignant tissue
Low power magnification Dissection of tumor tissue through anatomic structures of
the bowel wall with little or absent desmoplastic stromal
response (23)
“Circumscribed” configuration of the infiltrative
margin with desmoplastic stromal reaction
Irregular clusters, cords, or sharp wedges of long-stretched
tumor glands (23)
Absence of widely dissecting tumor glands
Residual host tissue is present between infiltrating glands
“Streaming dissection” (23)
Host tissue is displaced
“Expansile tumor growth”
Additional features Presence of perineural invasion (23) Absence of perineural infiltration
High-grade tumor budding is frequently observed (26) Low grade tumor budding is frequently observed
Peritumoral infiltration less pronounced (12) Often intense peritumoral inflammation
Molecular pathology features More frequently observed in cases with activating
BRAF-mutations (25)
More frequently observed in cases with
microsatellite instability (17–19)
Impact on clinical outcome in
transmurally invasive CRC
Unfavorable Favorable
verification in statistically robust studies with a specific focus on
stage II patients is clearly needed.
The association of tumor growth pattern with molecular fea-
tures of CRC represents an interesting vantage point for further
study. In particular, factors determining the directed growth of
CRC cells into host tissue remain to be determined. Further,
the influence of BRAF-mutations and MMR-deficiency on tumor
growth dynamics and plasticity may provide valuable insights into
the biology of CRC.
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